Rituximab: Mechanism of action and resistance

This publication has 25 references indexed in Scilit:

• Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment
  Journal of Clinical Oncology, 2000
• Rituximab (Anti‐CD20) Therapy of B‐Cell Lymphomas: Direct Complement Killing is Superior to Cellular Effector Mechanisms
  Scandinavian Journal of Immunology, 2000
• A receptor for phosphatidylserine-specific clearance of apoptotic cells
  Nature, 2000
• Clustered CD20 Induced Apoptosis: Src-Family Kinase, the Proximal Regulator of Tyrosine Phosphorylation, Calcium Influx, and Caspase 3-Dependent Apoptosis
  Blood Cells, Molecules, and Diseases, 2000
• Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
  Cancer Immunology, Immunotherapy, 2000
• Mice carrying a CD20 gene disruption
  Immunogenetics, 1998
• The association between CD20 and Src-family Tyrosine kinases requires an additional factor
  Molecular Immunology, 1998
• Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes.
  The Journal of cell biology, 1993
• Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum‐mediated lysis
  European Journal of Immunology, 1992
• Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes
  European Journal of Immunology, 1986